Pharma & Biotech Industry Analysis, from Thought Leaders
Refine Search
Pharmaceutical
For years, China has been viewed with a mixture of excitement, optimism and suspicion by western pharmaceutical firms, with nervous investors wary of the relatively opaque political and economic environment in the country. 22 January 2018
Biotechnology
It’s impossible to imagine how many lives antibiotics have saved since penicillin was first synthesized by Alexander Fleming in 1928 - certainly tens, if not hundreds of millions. 14 December 2017
Pharmaceutical
It is the third-most common disorder in the world. In the USA, close to 38 million people suffer from it. Globally, the number is a whopping 1 billion. We are talking about migraine, also often referred to as ‘super headaches’ — a condition more prevalent than diabetes, epilepsy, and asthma combined. 11 December 2017
Generics
A look at the drug prices that are not going up, and if the industry can cope if they drop further. 24 November 2017
Biotechnology
Alnylam Pharmaceuticals, which with some justification bills itself as the leading RNAi company, isn’t shy of mentioning the Nobel-prize winning provenance of its science and technology. 17 November 2017
Biotechnology
Thomas Busby and Oded Ben-Joseph, from investment bank Outcome Capital, look at some of the hurdles to accessing venture capital, and how companies can overcome them. 10 November 2017
Pharmaceutical
Michael Ellenbogen, who was diagnosed with younger-onset Alzheimer’s disease in 2008, was invited to give a talk to staff at a major pharma company last week. He has provided his speech to The Pharma Letter as part of his drive for urgent action to defeat the disease. 31 October 2017
Pharmaceutical
On November 20, the question of which country will host the European Medicines Agency post-Brexit will finally be settled, at the European Council’s General Affairs (Art. 50) meeting. 25 October 2017
Pharmaceutical
In this week's feature, Michael Jewell, the healthcare partner at Cavendish Corporate Finance, looks at a new initiative by Pfizer, the world’s largest pharmaceutical company, that aims to shake up the way the industry approaches nascent experimental drugs which would otherwise be side-lined. 17 October 2017
Pharmaceutical
A look into whether the issue of nationality matters when pharma companies are selecting their leaders. 6 October 2017
Pharmaceutical
Dr Nicola Davies explores pharmaceutical development in mental health, with a focus on factors that influence the road to pharma-psych innovation. 3 October 2017
Pharmaceutical
Yitzhak Peterburg, Teva’s last but one CEO, recently described the pharmaceutical industry as one of the last “traditional” industries, saying it was about to undergo “huge disruption.” 27 September 2017
Biotechnology
A fruitful congress of the European Society of Medical Oncology last week provided key insights into melanoma, lung, kidney and ovarian cancer research. 19 September 2017
Pharmaceutical
Nicola Davies casts her eye over a fast-emerging field in pharma. 13 September 2017
Pharmaceutical
A view on the future of rare disease drug development and population health from Michelle Hoffmann, senior vice president of strategy consulting at Boston-based life science consultancy, Back Bay Life Science Advisors. 4 September 2017
Pharmaceutical
Dr Nicola Davies debates the efficacy of US Food and Drug Administration approvals given the speed over safety angle. 30 August 2017
Biosimilars
A total of 32 biosimilar products, based on 12 biologics, have been approved for use in the European Union. This compares with just ten in the USA, referencing nine biologics. 22 August 2017
Biotechnology
A number of questions have been bouncing around the early-stage drug discovery community for a number of years now, particularly in the UK and Europe where a perception abounds that attractive funding opportunities are harder to come by than in the USA. 15 August 2017
Biotechnology
In March 2016, Barack Obama became the first US President to visit Cuba since 1928, marking one of the final stages in a progressive thaw in relations that, it was hoped, would usher in a new era of trade and cooperation between the two countries. 7 August 2017
Pharmaceutical
Twenty-first century data is providing the data-heavy pharma industry with a modern dilemma: how to preserve corporate information when technological development is accelerating so fast, writes Dominic Johnstone, head of information management services at Crown Records Management. 1 August 2017
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Pharmaceutical
An Analysis of M&A activity in the CNS space. 26 July 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
Anticipation had been building for many weeks, but when the UK’s general election finally took place on 4 July, the outcome felt entirely inevitable. 9 July 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
An analysis of the investment activity of Novartis in recent years. 5 April 2024
Pharmaceutical
An analysis of recent pharma activity in the metabolic diseases field and why obesity is a hot topic amongst investors. 8 March 2024
Pharmaceutical
When James Burt, the chief executive of lifecycle management healthcare company Pharmanovia, looks back at the mood in the pharma industry in 2023, he is happy to say that he is already experiencing a greater sense of optimism in 2024. 27 February 2024
Pharmaceutical
Danish drugmaker Lundbeck has its eye on steady growth over the medium term, a strategy which new chief executive Charl van Zyl believes could be key to the firm’s future success. 12 February 2024
Biotechnology
By Barbara Obstoj-Cardwell. Editor
In full year 2023, the total number of mergers and acquisitions (M&A) in the pharma and biotech sectors was 105, compared with 109 in 2022 and just 92 in 2021, according to tracking by The Pharma Letter (TPL). 4 January 2024
Biosimilars
In the two decades since biosimilars emerged on the world stage, their evolution has brought acceptance of the critical role they can play in making life-changing therapies more affordable. 22 December 2023
Pharmaceutical
A feature analyzing recent pharma activity in the hepatology field and why NASH remains unchartered territory. 20 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze